Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.

Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F.

Leukemia. 2012 Nov;26(11):2428-31. doi: 10.1038/leu.2012.153. Epub 2012 Jun 5. No abstract available.

2.

Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.

Singh SN, Cao Q, Gojo I, Rapoport AP, Akpek G.

Bone Marrow Transplant. 2012 Jul;47(7):1008-9. doi: 10.1038/bmt.2011.210. Epub 2011 Nov 14. No abstract available.

PMID:
22080965
3.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24309530
4.

Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.

Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.

Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.

PMID:
25263320
5.

Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.

Yamamoto R, Yokoyama A, Yoneda M, Ohashi K, Hosoda T, Kagoo T, Boku S, Ueno H, Yano T.

Ann Hematol. 2014 Dec;93(12):2081-2. doi: 10.1007/s00277-014-2119-8. Epub 2014 May 27. No abstract available.

PMID:
24863693
6.

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.

Bhatnagar B, Duong VH, Gourdin TS, Tidwell ML, Chen C, Ning Y, Emadi A, Sausville EA, Baer MR.

Leuk Lymphoma. 2014 Jul;55(7):1533-7. doi: 10.3109/10428194.2013.856425. Epub 2014 Feb 4.

PMID:
24144313
7.

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G.

Leukemia. 2012 May;26(5):1106-7. doi: 10.1038/leu.2011.342. Epub 2011 Nov 29. No abstract available.

8.

Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.

Kadia TM, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H.

Am J Hematol. 2015 Jul;90(7):E139-41. doi: 10.1002/ajh.24036. Epub 2015 May 28. No abstract available.

9.

Decitabine studies in chronic and acute myelogenous leukemia.

Kantarjian HM, O'Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, de Vos D, Talpaz M.

Leukemia. 1997 Mar;11 Suppl 1:S35-6. No abstract available.

PMID:
9130691
10.

Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.

Gupta N, Miller A, Gandhi S, Ford LA, Vigil CE, Griffiths EA, Thompson JE, Wetzler M, Wang ES.

Am J Hematol. 2015 Jul;90(7):639-46. doi: 10.1002/ajh.24016.

11.

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.

Park H, Chung H, Lee J, Jang J, Kim Y, Kim SJ, Kim JS, Min YH, Cheong JW.

Yonsei Med J. 2017 Jan;58(1):35-42. doi: 10.3349/ymj.2017.58.1.35.

12.

[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].

Gao S, Hu XH, Qiu HY, Xu Y, Jin ZM, He GS, Tang XW, Han Y, Chen SN, Sun AN, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019. Chinese. No abstract available.

PMID:
23827117
13.

Evidence for a role of decitabine in the treatment of myeloid sarcoma.

Gornicec M, Wölfler A, Stanzel S, Sill H, Zebisch A.

Ann Hematol. 2017 Mar;96(3):505-506. doi: 10.1007/s00277-016-2870-0. Epub 2016 Nov 6. No abstract available.

PMID:
27817041
14.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Estey EH.

Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12. Review.

PMID:
23757301
15.
16.

Decitabine in older adults with acute myeloid leukemia: why was the dream broken?

Kantarjian H, Wilson W, Ravandi F, Estey E.

J Clin Oncol. 2013 May 10;31(14):1795-6. doi: 10.1200/JCO.2012.48.1465. Epub 2013 Apr 1. No abstract available.

PMID:
23547076
17.

Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).

Ganguly S, Amin M, Divine C, Aljitawi OS, Abhyankar S, McGuirk JP.

Ann Hematol. 2013 Apr;92(4):549-50. doi: 10.1007/s00277-012-1607-y. Epub 2012 Oct 31. No abstract available.

PMID:
23111661
18.

Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.

Thomas S, Schelker R, Klobuch S, Zaiss S, Troppmann M, Rehli M, Haferlach T, Herr W, Reichle A.

Haematologica. 2015 Jan;100(1):e4-6. doi: 10.3324/haematol.2014.115055. Epub 2014 Sep 26. No abstract available.

19.

The role of hypomethylating agents in the treatment of elderly patients with AML.

Al-Ali HK, Jaekel N, Niederwieser D.

J Geriatr Oncol. 2014 Jan;5(1):89-105. doi: 10.1016/j.jgo.2013.08.004. Epub 2013 Sep 24. Review.

20.

Mixed-phenotype acute leukemia treated with decitabine.

Lee JY, Lee SM, Lee JY, Kim KH, Choi MY, Lee WS.

Korean J Intern Med. 2016 Mar;31(2):406-8. doi: 10.3904/kjim.2014.353. Epub 2016 Feb 15. No abstract available.

Supplemental Content

Support Center